Pmv Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · New Jersey, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
400 Alexander Park Ste 301, Princeton, N...Phone Number
(609) 642-6670Website
www.pmvpharma.comRevenue
-Stock Symbol
PMVPIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Pmv Pharmaceuticals
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases.Explore more
Pmv Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Pmv Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Pmv Pharmaceuticals
Earning: See what the market has to say on Pmv Pharmaceuticals recently announced quarterly report
Click to see if Pmv Pharmaceuticals had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Pmv Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Pmv Pharmaceuticals is spiking on competitors!
Funding: Get notified immidiatlly once Pmv Pharmaceuticals has new funding data
Product Launch: Get notified when Pmv Pharmaceuticals launches new products
Check if Pmv Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Pmv Pharmaceuticals
Find 2 more new buyers
Compare Similar Companies to Pmv Pharmaceuticals
Compare insights from companies similar to Pmv Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$35M
51-200
Public
$425M
2015
Kendra AdamsChief Financial Officer & Head Corporate Affairs & Principal Accounting Officer
<$5M
11-50
Public
$29.8M
1997
LW
Lauren WittberAssociate Director, Accounting, SEC Reporting & Financial Analysis
Company Profile Activity
Activity Insights
Pmv Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Pmv Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Pmv Pharmaceuticals.
Pmv Pharmaceuticals financials insights
Gather financial insights about Pmv Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$30M
2017
Series B
$74M
2019
Series C
$62M
2020
Series D
$70M
Stock Offering
$212M
2026
Stock/Share Issuance
$50M
Pmv Pharmaceuticals Tech Stack
A closer look at the technologies used by Pmv Pharmaceuticals
Most Recent Scoops
Open Position
Person-Based
Executive Move
Executive Moves, Board of Directors
Executive Move
Executive Moves, Board of Directors
Executive Move
Executive Moves, Board of Directors
Pmv Pharmaceuticals News & Media
PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push - Yahoo Finance
PMV Pharmaceuticals Inc. (NASDAQ:PMVP) on Monday shared interim data from its Phase 2 PYNNACLE trial for rezatapopt, an investigational treatment for ovarian cancer.Based on this data, the company announced its plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of the drug.Efficacy HighlightsThe interim data, gathered up to May 14, 2026, focus on patients with platinum-resistant or refractory ovarian cancer bearing the TP53 Y220CPMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities
PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, announced today the pricing of an underwritten public offering consisting of (i) 22,055,000 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase an aggregate of up to 19,900,000 shares of its common stock,PMV Pharma Announces Proposed Public Offering of Securities
PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, announced today that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock and, in lieu of common stock, to certain investors, pre-funded warrants to purchase shares of itsPMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial
PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced updated interim ovarian cancer data from the Phase 2 pivotal portion of the PYNNACLE clinical trial. The multicenter, single-arm, registrational Phase 2 trial is assessing rezatapopt as monotherapy at a dose of 2000 mg once-daily in patients with
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Pmv Pharmaceuticals
Sign Up For FreeTo access detailed company insights
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases.... Read More
